biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: oncology, neuroscience
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $200M

Partners & investors

  • ARCH Venture Partners· Investor
  • Lux Capital· Investor
  • a16z· Investor

Key considerations

  • ●AI tools in use: GEMS platform (GNN-based)
  • ●$200M Series B (2023) led by a16z + Lux Capital
  • ●Genentech partnership
  • ●ARCH Venture Partners backing

Pipeline

  • Preclinical1
Get live updates on Genesis Therapeutics’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Evan Feinberg

Co-Founder & CEO

graph-neural-networksmolecular-dynamics
Visit website →LinkedIn →